ProFrac Holding Corp. to Report Q4 and Full Year 2025 Financial Results

Quarterly Loss Report: ProFrac Holding Corp. reported a quarterly loss of $0.6 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.43, and a significant decline from a loss of $0.13 per share a year ago.

Revenue Performance: The company generated revenues of $403.1 million for the quarter, missing the consensus estimate by 0.58% and down from $575.3 million in the same quarter last year.

Stock Outlook: ProFrac's stock has underperformed, losing about 35.2% since the beginning of the year, and currently holds a Zacks Rank #5 (Strong Sell), indicating expectations of further underperformance in the near future.

Industry Context: The Oil and Gas - Field Services industry is currently ranked in the bottom 40% of Zacks industries, which may negatively impact ProFrac's stock performance, while another sector company, National Energy Services Reunited, is set to report its earnings soon.

U.S. Stock Futures: U.S. stock futures rose this morning, with Nasdaq futures increasing by approximately 1.5% on Monday.

Monday.Com Earnings: Shares of Monday.Com Ltd fell 2.6% in pre-market trading ahead of its quarterly earnings report, with analysts expecting earnings of 88 cents per share and revenue of $312.26 million.

Other Stocks Declining: Several stocks experienced declines in pre-market trading, including Metsera Inc, which dropped 15% after Pfizer's $10 billion acquisition deal, and Ionis Pharmaceuticals, which fell 11.5% following disappointing study results.

Market Overview: Other notable declines included Oscar Health Inc down 5.4%, Centene Corp down 4.8%, and Profrac Holding Corp down 2.8%, reflecting a generally negative trend among various stocks.

Q3 Financial Performance: ProFrac Holding reported Q3 revenue of $403.1 million, a 29.9% year-over-year decline, missing expectations by $16.19 million. The net loss was $92 million, an improvement from the $107 million loss in Q2 2025.

Adjusted EBITDA and Cash Flow: Adjusted EBITDA decreased to $41 million, representing 10% of revenue, down from 16% in Q2 2025. Net cash from operating activities fell to $5 million, and free cash flow was negative at $(29) million.

Outlook for Stimulation Services: The company anticipates improved activity levels in the Stimulation Services segment for Q4, despite expected lower pricing compared to Q3. Sequential improvement in results is expected.

Proppant Production Segment Expectations: ProFrac expects profitability in the Proppant Production segment to improve in Q4, driven by enhanced operational efficiency and increased throughput, despite ongoing pricing pressures.

Jim Cramer's Take on Zoom: Jim Cramer stated that while Zoom Communications Inc. is a solid company, it currently lacks a catalyst for investment, advising to "take a pass" until after their Q3 financial results on Nov. 24.

ProFrac Holding Corp Outlook: Cramer expressed a negative stance on oil stocks, including ProFrac Holding Corp, stating he is "really anti the oils right now," and noted a recent downgrade in ProFrac's price target by Piper Sandler.

Viking Therapeutics Performance: Cramer recommended Eli Lilly over Viking Therapeutics, which reported a quarterly loss that exceeded analyst expectations, leading to a 3.8% drop in its share price.

Altria Group Earnings: Cramer refrained from recommending Altria Group but acknowledged its recent earnings report, which met expectations despite a decline in quarterly sales, resulting in a slight increase in its share price.